Clinical Trial Update: Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating LMB-100 with tofacitinib in previously treated mesothelin-expressing solid tumors, including pancreatic adenocarcinoma and cholangiocar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Epithelioid Mesothelioma
• Neoplasms with Mesothelin Expression
• Pancreatic Adenocarcinoma

Drugs mentioned

• LMB-100 (mesothelin-targeted immunotoxin)
• Tofacitinib (tofacitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma | Phase 1 | Status: COMPLETED | Results posted: 2022-02-08